arsenic trioxide has been researched along with Liver Neoplasms in 121 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.83) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 32 (26.45) | 29.6817 |
| 2010's | 61 (50.41) | 24.3611 |
| 2020's | 27 (22.31) | 2.80 |
| Authors | Studies |
|---|---|
| Li, C; Li, F; Liu, A; Piao, JG; Wei, Y; Yue, T; Zhang, K; Zheng, H | 1 |
| Huang, JB; Jiang, T; Lou, ZH; Lu, J; Lv, YL; Xu, CY; Yang, DQ; Zhang, GJ; Zhao, ZQ | 1 |
| Cai, X; Chen, D; Han, S; Huang, Y; Wei, Y; Xu, Z | 1 |
| Dong, S; Gao, J; Kong, J; Li, Z; Sun, W; Wu, S | 1 |
| Ali, M; Bhardwaj, SK; Chaudhary, A; Haque, R; Khan, A; Sinha, KK; Srivastava, A | 1 |
| Chen, L; Gu, J; Ji, H; Liu, J; Song, W; Song, X; Wu, J; Zhang, S | 1 |
| Chen, J; Gu, J; Guo, J; Hu, X; Li, D; Li, X; Liu, J; Mei, C; Peng, C; Xiao, Y; Zhang, K; Zhang, X; Zhou, B | 1 |
| Cheng, M; Li, B; Li, F; Piao, JG; Sun, J; Wei, Y; Ye, T; Zheng, H; Zhou, M | 1 |
| Aki, T; Funakoshi, T; Kukita, M; Takata, M; Uemura, K; Unuma, K | 1 |
| Chen, J; Chen, S; Luo, H; Wang, S; Wu, W | 1 |
| Jiang, L; Qiu, M; Raza, F; Su, J; Wang, X; Yuan, WE; Zhong, H | 1 |
| Alqahtani, MA; El-Ghiaty, MA; El-Kadi, AOS | 1 |
| He, R; Huang, J; Liu, S; Pan, X; Shao, Y; Shi, T; Xi, J; Yu, W; Zhuang, R | 1 |
| He, B; Qiu, M; Raza, F; Su, J; Yuan, WE; Zheng, M; Zhong, H | 1 |
| Chen, J; Du, D; Liu, C; Wu, Y | 1 |
| Chen, L; Chen, X; Han, X; Meng, X; Qi, X; Wang, P; Wu, Q; Xu, K | 1 |
| Li, X; Sun, D; Zhang, Z; Zhao, T | 1 |
| Chen, PF; Duan, XH; Han, XW; Ju, SG; Li, FY; Li, H; Ren, JZ; Wu, YY | 1 |
| Cai, X; Chen, Z; Jin, P; Ren, Z; Ye, F; Yu, L | 1 |
| Guo, T; Hu, Y; Li, Y; Su, Y; Xue, J | 1 |
| Chen, L; Huang, MH; Li, YS; Liang, QR; Liu, ZX; Luo, RG; Tang, Q; Xu, YH; Zhao, J | 1 |
| Duan, J; Song, H; Wang, X; Yang, L; Zhang, F; Zhou, M | 1 |
| Carroll, SL; Feng, G; Jiang, T; Jiang, X; Kong, D; Liu, B; Liu, J; Lou, C; Zhao, B | 1 |
| Cao, Y; Cheng, JW; Fan, J; Hu, B; Huang, A; Huang, XW; Qiu, SJ; Sun, YF; Yang, XR; Zeng, HY; Zhang, X; Zhou, J | 1 |
| Hu, Y; Li, S; Liu, H; Xie, Y; Xu, X; Yan, D; Zhao, Z; Zou, Y | 1 |
| Chen, D; Chen, Y; Jiang, X; Li, D; Li, H; Shan, H; Wang, W | 1 |
| Gu, SY; Li, Y; Zhang, ZZ | 1 |
| Du, P; Lu, W; Yang, C; Zhang, JC; Zhang, JL | 1 |
| Fu, Y; Guo, BB; Jiang, HY; Li, S; Liu, LY; Wang, KK; Wu, CJ; Zhang, CM; Zhang, F; Zhang, Y | 1 |
| Chen, CF; Chern, CL; Ho, CT; Lin, LC; Liu, JJ; Liu, TZ | 1 |
| Hai, Y; Li, H; Li, Y; Ma, W; Song, P; Wang, X; Wu, Z; Xie, Q; Zhao, L | 1 |
| Ali, M; Ali, V; Bimal, S; Haque, R; Kumar, N; Sadaf, N | 1 |
| Cui, Z; Fan, C; Kong, H; Shi, J; Wang, L; Xia, K; Yan, Q; Zhang, J; Zhang, Y; Zhu, Y; Zuo, X | 1 |
| Dai, Y; Huang, G; Jiang, Z; Jiao, R; Jin, M; Ju, L; Li, Y; Lu, M; Qiu, Y; Shan, W; Shen, J; Tang, Z; Wang, Y; Wong, VKW; Xia, Y; Yang, L; Yang, Y; Zhang, C; Zhang, J | 1 |
| Fan, Z; Fu, T; He, J; Liu, R; Lv, L; Qu, X; Wang, J; Yang, G; Zhang, W | 1 |
| He, LJ; Jia, YL; Nan, X; Pei, XT; Wang, DX; Wang, HY; Xi, JF; Xu, YC; Yue, W; Zeng, Q; Zhang, B; Zhou, JN | 1 |
| Ji, S; Li, W; Wang, L; Wang, M; Zhang, C; Zhang, J | 1 |
| Ao, JY; Bu, Y; Chai, ZT; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Zhang, KZ; Zhang, QB; Zhang, YY; Zhu, XD | 1 |
| Jiang, F; Li, Y; Li, Z; Mu, J; Ning, S; Si, L; Wang, X; Ye, X | 1 |
| Fang, ZT; Li, S; Liu, R; Qian, S; Qu, XD; Wang, GZ; Wang, JH; Wang, LL; Yang, GW; Yang, MJ; Zhang, W; Zhang, WS; Zhu, L | 1 |
| Fan, Z; Huaqun, F; Kai, W; Kaiyang, W; Linquan, W; Mingwen, H; Xiangbao, Y; Xin, Y | 1 |
| Chen, X; Jiang, H; Li, Y; Liang, Y; Liu, J; Liu, L; Lu, Z; Meng, X; Pan, S; Qi, S; Song, X; Sun, B; Wang, J; Xie, C; Yin, D; Zheng, T | 1 |
| Akrami, SM; Habibi, L; Karimi, A; Madjd, Z | 1 |
| Fu, HQ; Huang, MW; Wang, K; Wang, KY; Wu, LQ; Yin, XB; Yu, X; Zhou, F | 1 |
| Liu, F; Wang, W; Wei, J; Ye, C | 1 |
| Jiang, F; Li, Y; Li, Z; Liu, Q; Shen, J; Wang, X; Zhang, J | 1 |
| Jiang, F; Li, Y; Li, Z; Liu, Q; Lu, X; Shen, J; Wang, X; Zhang, J | 1 |
| Chen, CZ; Hu, YN; Jiang, XJ; Zhang, ZZ; Zhao, W | 1 |
| He, C; Jiang, H; Jiang, X; Ma, L; Sun, X; Xu, L; Zhai, B; Zhao, D | 1 |
| Ling, S; Sun, D; Tian, Y; Wang, L; Yang, X | 1 |
| Deng, J; Li, Y; Luo, Q; Zhang, Z | 1 |
| He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhao, W; Zheng, YB | 1 |
| Deng, JJ; Li, Y; Luo, QY; Zhang, ZZ | 1 |
| Lai, Y; Li, Y; Luo, Q; Zhang, Z | 1 |
| Jin, G; Liu, D; Liu, Y; Sun, Z; Wang, C; Wang, H; Wang, X; Yu, S; Zhang, B | 1 |
| Gao, B; Lu, M; Meng, X; Miao, Z; Qiao, X; Wu, L; Xue, D; Zhang, W | 1 |
| Cao, Y; Fan, J; He, YF; Hu, B; Huang, XW; Qiu, SJ; Sun, C; Sun, YF; Wang, Z; Yang, XR; Zeng, HY; Zhang, X; Zhou, J | 1 |
| Cao, Z; Chen, X; Cui, L; Gao, B; Zhang, S; Zhang, W | 1 |
| Chi, X; Gao, J; Liu, H; Shan, H; Zhang, Z; Zhao, Z; Zhou, H; Zhu, X | 1 |
| Chen, C; Hu, H; Li, H | 1 |
| Chen, FY; Gu, ZJ; Kulkarni, P; Li, JQ; Li, L; Liu, L; Mason, RP; Tang, BB; Tang, Q; Yi, JW | 1 |
| Gu, SY; Hu, YN; Zhang, ZZ | 1 |
| Chen, M; Cheng, X; Fan, X; Ji, J; Song, J; Wu, F; Ying, X; Zhang, D; Zhao, Z | 1 |
| Chang, Y; Jiang, M; Zhou, Q; Zhou, R; Zhu, C | 1 |
| Fan, L; Liang, K; Liang, W; Peng, G; Wang, L; Wang, R; Xu, Y; Ye, Q | 1 |
| Fei, W; Han, S; Li, F; Tao, J; Wang, X; Wei, Y; Zhang, Y; Zheng, H; Zhu, J | 1 |
| Gao, F; Liu, Y; Song, W | 1 |
| Lou, Z; Shen, L; Xu, G; Zhang, G | 1 |
| Lv, XH; Wang, CH; Xie, Y | 1 |
| Cheng, C; Cui, X; Fei, M; Gao, S; He, S; Ke, Q; Li, P; Liu, Y; Lu, M; Shen, A; Wang, Y; Zhao, Y | 1 |
| Aklilu, M; Kindler, HL; Nattam, S; Vokes, EE | 1 |
| Cao, EH; Liang, XQ; Liu, XM; Song, Y; Tang, RJ; Xiong, XF | 1 |
| Chen, X; Liu, LX; Zhang, M | 1 |
| Song, J; Wang, ZY; Zhang, DS | 1 |
| Jiang, HC; Liu, TF; Song, PL; Sun, B; Zhao, XS | 1 |
| Chen, X; Jiang, H; Krissansen, GW; Ma, Y; Pan, S; Sun, B; Sun, X | 1 |
| Chen, X; Jiang, H; Liu, L; Ma, Y; Pan, S; Sun, X; Wang, J; Zhu, H | 1 |
| Chen, X; Jiang, HC; Liu, LX; Meng, XZ; Pan, SH; Wang, JB; Zhang, WH; Zheng, TS | 1 |
| Chang, YJ; Cheng, YW; Chiou, JF; Hsieh, PY; Hsu, CH; Ko, HL; Liu, TZ; Ting, LL; Tung, JN; Wu, AT | 1 |
| Han, H; Jiang, T; Lu, H; Luo, R; Shen, P | 1 |
| Chen, BA; Liu, L; Qin, SK | 1 |
| Gu, N; Li, GZ; Lu, Q; Niu, HZ; Teng, GJ; Wang, ZY; Xu, RZ; Yu, H; Zhang, DS; Zhu, GY | 1 |
| Chen, C; Huang, D; Qi, Y; Wang, Y; Xi, Y; Zhang, Y | 1 |
| Hua, H; Li, J; Qin, S; Rui, J | 1 |
| Hong, DY; Huang, HS; Liu, ZM; Tseng, JT | 1 |
| Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C | 1 |
| Bian, J; Guo, J; Wang, Y; Wu, H; Wu, X; Zhang, C; Zhang, S; Zhou, J | 1 |
| Chen, G; Chen, JX; Hua, ZC; Tang, B; Wang, K; Yang, BY | 1 |
| Chen, Q; Hao, XZ; Liu, JW; Qin, SK; Qu, FL; Qu, T; Sui, GJ; Sun, Y; Zhang, HP | 1 |
| Jia, S; Yang, S; Yang, T; Yang, Y; Zhang, X | 1 |
| Allensworth, JL; Devi, GR; Diehl, AM; Lyerly, HK; Morse, MA; Rangwala, F; Smith, GR; Thomas, Z; Williams, KP | 1 |
| Cao, LM; Li, HY | 1 |
| Cheng, HT; Guo, CY; Hu, HT; Li, HL; Luo, JP; Meng, YL; Xiao, JC; Yao, QJ | 1 |
| Chen, CX; Huang, FL; Wang, HN; Wang, YL | 1 |
| Allain, N; Fardel, O; Guillouzo, A; Le Vée, M; Morel, F; Vernhet, L | 1 |
| Liu, JW; Shen, Y; Tang, Y; Zhong, XY | 1 |
| Chen, GQ; Chen, Z; Jing, Y; Styblo, M; Walton, F; Waxman, S; Weinberg, R; Zhou, L | 1 |
| Hong, L; Qi, QH; Wang, SS; Wang, XL; Zhang, T | 1 |
| Wang, ZH; Yu, D; Zhu, LY | 1 |
| Akao, Y; Futatsugawa, S; Kito, M; Matsumoto, K; Naoe, T; Nozawa, Y; Sera, K; Wada, N | 1 |
| Dorsey, WC; Tchounwou, PB; Yedjou, CG | 1 |
| Li, JT; Ou, QJ; Wu, YC | 1 |
| Ahmed, M; Gazelle, GS; Goldberg, SN; Horkan, C; Kruskal, JB; Liu, Z; Solazzo, SA | 1 |
| Chen, H; Hua, HQ; Qin, SK; Wang, JH | 1 |
| Chen, W; Guo, HX; Jiang, HC; Liu, LX; Liu, ZH; Wang, XQ; Wu, M; Zhang, TD; Zhu, AL | 1 |
| Dong, X; Jiang, H; Kanwar, JR; Krissansen, GW; Luo, L; Meng, F; Qiao, H; Sun, X; Zhou, B | 1 |
| Cui, X; Hatakeyama, K; Hirano, S; Shirai, Y; Wakai, T; Yokoyama, N | 1 |
| Fu, Q; Hu, BR; Li, JJ; Li, Y; Ming, ZY; Qian, JQ; Tang, Q; Xiang, JZ | 1 |
| Cheng, AL; Hsu, C; Hsu, CH; Hsu, WL; Lin, CC; Yang, CH | 1 |
| Kumar, R; Mukhopadhyay, AK; Paul, MK | 1 |
| Cui, XP; Li, P; Lu, MD; Shen, AG; Wang, Y | 1 |
| Chen, Q; Gao, P; Jin, H; Tian, C; Wang, X; Yue, W; Zheng, Y | 1 |
| Cui, YZ; Luo, RC; Wu, J; Zhang, H | 1 |
| Eichner, D; Gottschalk, D; Gottschalk, I; Norpoth, K; Schmidt, EH; Thomas, H; Witting, U | 1 |
| Chen, H; Liu, L; Liu, W; Ma, J; Qin, S; Wang, J | 1 |
| Ishaque, AB; Schneider, J; Tchounwou, PB; Wilson, BA | 1 |
| Chen, Y; He, Z; Liu, X; Qian, J; Qin, S; Shao, Z; Wang, L | 1 |
| He, Z; Qian, J; Qin, S | 1 |
| Akao, Y; Kito, M; Nozawa, Y; Ohishi, N; Yagi, K | 1 |
| Chan, JY; Fung, KP; Siu, KP | 1 |
| Chen, D; Chen, L; Fan, T; Gao, Z; Jiang, Y; Li, Y; Liu, Z; Qiu, Z; Wai Wong, VK; Wu, W; Yang, M; Zhang, C; Zhou, Y | 1 |
4 review(s) available for arsenic trioxide and Liver Neoplasms
| Article | Year |
|---|---|
Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Oxides | 2022 |
The application of arsenic trioxide in cancer: An umbrella review of meta-analyses based on randomized controlled trials.
Topics: Arsenic Trioxide; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Randomized Controlled Trials as Topic; Tretinoin | 2023 |
Arsenic trioxide combined with transarterial chemoembolization for unresectable primary hepatic carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Oxides; Quality of Life; Survival Rate; Treatment Outcome | 2018 |
Arsenic trioxide combined with transarterial chemoembolization for primary liver cancer: A meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Databases, Bibliographic; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Oxides; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2017 |
9 trial(s) available for arsenic trioxide and Liver Neoplasms
| Article | Year |
|---|---|
Arsenic trioxide-eluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients.
Topics: Adult; Aged; Arsenic Trioxide; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Delivery Systems; Ethiodized Oil; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Microspheres; Middle Aged; Treatment Outcome | 2020 |
Effects of arsenic trioxide on the expression of ezrin in hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cytoskeletal Proteins; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Oxides | 2017 |
Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Combined Modality Therapy; Drug Administration Schedule; Female; Hepatic Artery; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxides; Single-Blind Method; Treatment Outcome; Tumor Burden | 2015 |
Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Oxides; Proportional Hazards Models; Treatment Outcome | 2015 |
Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
[Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Half-Life; Humans; Injections; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Oxides; Quality of Life; Remission Induction; Survival Rate; Vomiting | 2011 |
[The clinical therapeutic effects of arsenic trioxide combined with transcatheter arterial chemoembolization in treating primary liver cancer with pulmonary metastases].
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxides; Treatment Outcome | 2012 |
Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Drug Administration Schedule; Fatigue; Female; Humans; Injections, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxides; Survival Analysis; Treatment Outcome | 2007 |
[Arsenic trioxide for the treatment of medium and advanced primary liver cancer].
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Female; Humans; Liver Neoplasms; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome; Vomiting | 2002 |
108 other study(ies) available for arsenic trioxide and Liver Neoplasms
| Article | Year |
|---|---|
MMP2-responsive dual-targeting drug delivery system for valence-controlled arsenic trioxide prodrug delivery against hepatic carcinoma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Delivery Systems; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Prodrugs; Tissue Distribution; Tumor Microenvironment | 2021 |
Arsenic Trioxide Cooperate Cryptotanshinone Exerts Antitumor Effect by Medicating Macrophage Polarization through Glycolysis.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Carcinoma, Hepatocellular; Cell Differentiation; Cytokines; Drug Combinations; Drug Synergism; Drugs, Chinese Herbal; Glycolysis; Humans; Immunity, Innate; Immunomodulation; Liver Neoplasms; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C; Phenanthrenes; Th1 Cells | 2022 |
Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy.
Topics: Albumins; Animals; Antineoplastic Agents; Arsenic Trioxide; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Mice; Nanoparticles; Polyethylene Glycols; Polyethyleneimine; Transcytosis; Tumor Microenvironment | 2022 |
Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2.
Topics: Angiopoietin-1; Angiopoietin-2; Animals; Arsenic Trioxide; Carcinoma, Hepatocellular; Cell Line, Tumor; Endothelial Cells; Liver Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Radiofrequency Ablation | 2022 |
Combinatorial Effect of Arsenic and Herbal Compounds in Telomerase-Mediated Apoptosis Induction in Liver Cancer.
Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Emodin; Humans; Liver Neoplasms; Oxides; Quercetin; Telomerase | 2023 |
Thiolated chitosan nanoparticles for stable delivery and smart release of As
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Cell Line, Tumor; Chitosan; Drug Carriers; Glutathione; Liver Neoplasms; Mice; Nanoparticles | 2023 |
Arsenic-Loaded Biomimetic Iron Oxide Nanoparticles for Enhanced Ferroptosis-Inducing Therapy of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Biomimetics; Carcinoma, Hepatocellular; Cell Line, Tumor; Ferroptosis; Liver Neoplasms; Magnetic Iron Oxide Nanoparticles; Mice | 2023 |
Induction of filamin-C and its involvement in the regulation of cellular senescence and apoptosis in Huh-7 hepatoma cells during arsenic trioxide exposure.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cellular Senescence; Filamins; Humans; Liver Neoplasms; Oxides | 2023 |
PEG-grafted arsenic trioxide-loaded mesoporous silica nanoparticles endowed with pH-triggered delivery for liver cancer therapy.
Topics: Arsenic Trioxide; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Liver Neoplasms; Nanoparticles; Silicon Dioxide; Tumor Microenvironment | 2023 |
Arsenic trioxide (ATO) up-regulates cytochrome P450 1A (CYP1A) enzymes in murine hepatoma Hepa-1c1c7 cell line.
Topics: Animals; Arsenic Trioxide; Carcinoma, Hepatocellular; Cell Line; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Liver Neoplasms; Mice; Polychlorinated Dibenzodioxins; Receptors, Aryl Hydrocarbon; RNA, Messenger | 2023 |
pH-Responsive and liver-targeting drug delivery system for combination delivery of artesunate with arsenic trioxide prodrug against hepatocellular carcinoma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Artesunate; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Liposomes; Liver Neoplasms; Polyethylene Glycols; Prodrugs | 2023 |
Engineered tumor microvesicles modified by SP94 peptide for arsenic trioxide targeting drug delivery in liver cancer therapy.
Topics: Arsenic Trioxide; Drug Delivery Systems; Humans; Liver Neoplasms; Peptides; Tumor Microenvironment | 2023 |
Preparation of PLGA microspheres loaded with 10-hydroxycamptothecin and arsenic trioxide and their treatment for rabbit hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Camptothecin; Carcinoma, Hepatocellular; Disease Models, Animal; Liver Neoplasms; Microspheres; Polylactic Acid-Polyglycolic Acid Copolymer; Rabbits | 2021 |
Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Hep G2 Cells; Humans; Hyperthermia, Induced; Liver Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Mitochondria; Nanoparticles; Particle Size; Xenograft Model Antitumor Assays; Zirconium | 2020 |
Long non-coding RNA ROR confers arsenic trioxide resistance to HepG2 cells by inhibiting p53 expression.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; RNA, Long Noncoding; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2020 |
Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1.
Topics: Animals; Apoptosis; Arsenic Trioxide; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Computational Biology; DNA-Binding Proteins; Female; Gain of Function Mutation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; MicroRNAs; Nuclear Proteins; Proto-Oncogene Mas; Proto-Oncogene Proteins c-pim-1; TEA Domain Transcription Factors; Transcription Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Studies on the Inhibitory Effects of Nano-Hydroxyapatite-Loaded As₂O₃ on Hepatoma Cells.
Topics: Arsenic Trioxide; Carcinoma, Hepatocellular; Durapatite; Humans; Liver Neoplasms; Nanoparticles; Particle Size | 2020 |
Nanosized drug-eluting bead for transcatheter arterial chemoembolization (ND-TACE).
Topics: Animals; Arsenic Trioxide; Arsenites; Chemoembolization, Therapeutic; Dextrans; Drug Carriers; Drug Liberation; Gadolinium; Liver Neoplasms; Nanoparticles; Rabbits; Sodium Compounds | 2020 |
Combination of canstatin and arsenic trioxide suppresses the development of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Collagen Type IV; Humans; Liver Neoplasms; Mice; Mice, Nude; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Line, Tumor; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice, Nude; Microspheres; Polylactic Acid-Polyglycolic Acid Copolymer; Reactive Oxygen Species; Solvents; Xenograft Model Antitumor Assays | 2020 |
Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Female; Fluorouracil; Humans; Janus Kinase 1; Leukemia Inhibitory Factor; Liver Neoplasms; Male; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; NF-kappa B; Real-Time Polymerase Chain Reaction; Signal Transduction; STAT3 Transcription Factor | 2021 |
Investigation of the Physical Properties and Clinical Application of Embosphere Microspheres.
Topics: Angiography; Arsenic Trioxide; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Carriers; Fluorouracil; Gelatin; Hepatic Artery; Humans; Liver Neoplasms; Microspheres; Oils; Particle Size | 2021 |
Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression.
Topics: Animals; Arsenic Trioxide; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Mice; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A | 2022 |
[Effect of Cell Autophagy on the Apoptosis of Hepatocellular Carcinoma Cells Induced by Arsenic Trioxide].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Beclin-1; Carcinoma, Hepatocellular; Hep G2 Cells; Humans; Liver Neoplasms; Microtubule-Associated Proteins | 2017 |
Low dosage of arsenic trioxide inhibits vasculogenic mimicry in hepatoblastoma without cell apoptosis.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Hepatoblastoma; Humans; Liver Neoplasms; Male; Mice, Nude; Neovascularization, Pathologic; Oxides; Xenograft Model Antitumor Assays | 2018 |
γ-Glutamylcysteine synthetase (γ-GCS) as a target for overcoming chemo- and radio-resistance of human hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Catalysis; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Glutamate-Cysteine Ligase; Hep G2 Cells; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Oxides; Radiation Tolerance; Reactive Oxygen Species | 2018 |
Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Humans; Liver Neoplasms; Oxides; Receptors, Notch | 2018 |
Nanodiamond autophagy inhibitor allosterically improves the arsenical-based therapy of solid tumors.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Autophagy; Carcinoma; Drug Therapy, Combination; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Nanodiamonds | 2018 |
Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3η/NF-κB feedback loop.
Topics: 14-3-3 Proteins; Arsenic Trioxide; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Feedback, Physiological; Humans; Liver Neoplasms; NF-kappa B; Signal Transduction; Transfection | 2018 |
Arsenic trioxide inhibits EMT in hepatocellular carcinoma by promoting lncRNA MEG3 via PKM2.
Topics: Arsenic Trioxide; Carcinoma, Hepatocellular; Carrier Proteins; Cell Movement; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Membrane Proteins; RNA, Long Noncoding; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Tumor Cells, Cultured | 2019 |
Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Minichromosome Maintenance Complex Component 7; Neoplastic Stem Cells; Prognosis; Serum Response Factor; Transplantation, Heterologous | 2019 |
Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Flavonoids; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Oxides; Reactive Oxygen Species; Transplantation, Heterologous | 2014 |
Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model.
Topics: AC133 Antigen; Animals; Antigens, CD; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Glycoproteins; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oxides; Peptides; Random Allocation; Signal Transduction; Survival Analysis; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2014 |
Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491.
Topics: Arsenic Trioxide; Arsenicals; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Neoplasm Invasiveness; NF-kappa B; Oxides; Signal Transduction | 2014 |
Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Embolization, Therapeutic; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Oxides; Rats; Rats, Inbred BUF; Twist-Related Protein 1 | 2014 |
Humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles, an antibody conjugate with potent and selective anti-hepatocellular carcinoma activity.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Immunohistochemistry; Leukocyte Count; Liver Neoplasms; Male; Mice, Nude; Microvessels; Nanoparticles; Oxides; Platelet Count; Single-Chain Antibodies; Tissue Distribution; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Nuclear Proteins; Oxides; Piperazines; Signal Transduction; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2014 |
Exposure of hepatocellular carcinoma cells to low-level As₂O₃ causes an extra toxicity pathway via L1 retrotransposition induction.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Coloring Agents; Deoxyribonuclease I; DNA; Flow Cytometry; Green Fluorescent Proteins; Humans; Indicators and Reagents; Liver Neoplasms; Liver Neoplasms, Experimental; Microscopy, Fluorescence; Oxides; Plasmids; Real-Time Polymerase Chain Reaction; Retroelements; Tetrazolium Salts; Thiazoles; Transfection | 2014 |
Inhibitory effect of humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles conjugate on growth of human hepatocellular carcinoma: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Delivery Systems; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Microvessels; Nanoparticles; Neovascularization, Pathologic; Oxides; Single-Chain Antibodies; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
All-trans retinoic acid and arsenic trioxide induce apoptosis and modulate intracellular concentrations of calcium in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Carcinoma, Hepatocellular; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Oxides; Tretinoin | 2014 |
Inhibition of TGF-β/SMAD3/NF-κB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells.
Topics: 3' Untranslated Regions; Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Methylation; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; MicroRNAs; Neovascularization, Pathologic; Neovascularization, Physiologic; NF-kappa B; Oxides; RNA Interference; Signal Transduction; Smad3 Protein; Time Factors; Transfection; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2014 |
Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Topics: 3' Untranslated Regions; AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplastic Stem Cells; Oxides; Peptides; RNA Interference; Signal Transduction; Smad3 Protein; Time Factors; Transfection; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2015 |
[The apoptotic mechanism of hepatocellular carcinoma cell line (HepG2) induced by arsenic trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Glutamate-Cysteine Ligase; Glutathione; Hep G2 Cells; Humans; Liver Neoplasms; Oxides; Reactive Oxygen Species | 2014 |
Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Neoplasm Proteins; Niacinamide; Oxides; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2015 |
Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Metformin; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2015 |
PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair.
Topics: 1-Naphthylamine; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cyclin B1; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; Liver Neoplasms; M Phase Cell Cycle Checkpoints; Naphthalimides; Oxides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Quinolones; Up-Regulation | 2015 |
[4-amino-1,8-naphthalimide on the Sensitive effect of arsenic trioxide in hepatocellular carcinoma cells].
Topics: 1-Naphthylamine; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Survival; DNA Damage; DNA Repair; Hep G2 Cells; Humans; Liver Neoplasms; Naphthalimides; Oxides; Quinolones | 2015 |
The role of NF-κB in PARP-inhibitor-mediated sensitization and detoxification of arsenic trioxide in hepatocellular carcinoma cells.
Topics: 1-Naphthylamine; Acetylcysteine; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; DNA Damage; Hep G2 Cells; Humans; Inactivation, Metabolic; Liver Neoplasms; Naphthalimides; NF-kappa B; Oxidative Stress; Oxides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinolones; Reactive Oxygen Species | 2015 |
Analysis of the transcriptional regulation of cancer-related genes by aberrant DNA methylation of the cis-regulation sites in the promoter region during hepatocyte carcinogenesis caused by arsenic.
Topics: Amino Acid Motifs; Arsenic Trioxide; Arsenicals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinogenesis; Cell Line; Cell Transformation, Neoplastic; Computational Biology; DNA Methylation; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver; Liver Neoplasms; Oligonucleotide Array Sequence Analysis; Oxides; Promoter Regions, Genetic; RNA, Messenger; Signal Transduction; Transcription Factors; Transcriptional Activation; Wnt Proteins | 2015 |
Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Topics: Adult; Aged; Aldehyde Dehydrogenase; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Middle Aged; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins | 2015 |
Downregulation of B7-H4 in the MHCC97-H hepatocellular carcinoma cell line by arsenic trioxide.
Topics: Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 2; Liver Neoplasms; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Oxides; RNA, Messenger; Signal Transduction; STAT3 Transcription Factor; V-Set Domain-Containing T-Cell Activation Inhibitor 1; Vascular Endothelial Growth Factor A | 2016 |
A facile route to core-shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Female; Humans; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Mice; Mice, Inbred ICR; Microscopy, Electron, Transmission; Nanoparticles; Oxides; Porosity; Silicon Dioxide; Surface Properties; Transplantation, Heterologous | 2016 |
[Treatment of refractory pulmonary metastases from hepatocellular carcinoma by transcatheter arterial chemoembolization using arsenic trioxide in combination with sorafinib].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Oxides; Phenylurea Compounds; Sorafenib | 2015 |
Inorganic phosphate-triggered release of anti-cancer arsenic trioxide from a self-delivery system: an in vitro and in vivo study.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Movement; Dextrans; Drug Delivery Systems; Female; Hep G2 Cells; Humans; Kinetics; Liver Neoplasms; Mice; Microscopy, Electron, Transmission; Nanoparticles; Neoplasm Invasiveness; Neoplasm Transplantation; Oxides; Phosphates; Rats; Spectroscopy, Fourier Transform Infrared; Thermodynamics | 2016 |
[The Experiment Study and Mechanism of Aspirin Enhances Cellular Sensitivity of Hepatocellular Carcinoma Cell Line to Arsenic Trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Flow Cytometry; Heme Oxygenase-1; Humans; Liver Neoplasms; NF-E2-Related Factor 2; Oxides; Reactive Oxygen Species | 2016 |
Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; DNA Damage; Drug Synergism; Endoplasmic Reticulum Stress; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Nude; Naphthoquinones; Oxides; Xenograft Model Antitumor Assays | 2016 |
microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Male; Mice, Nude; MicroRNAs; Oxides | 2016 |
Arsenic trioxide is an immune adjuvant in liver cancer treatment.
Topics: Adjuvants, Immunologic; Animals; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cytokine-Induced Killer Cells; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorescent Antibody Technique; Humans; Liver Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Mice; Oxides; Real-Time Polymerase Chain Reaction; T-Lymphocytes; Xenograft Model Antitumor Assays | 2017 |
RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liposomes; Liver Neoplasms; MCF-7 Cells; Mice; Nanoparticles; Oligopeptides; Oxides; Silicon Dioxide | 2017 |
Periostin contributes to arsenic trioxide resistance in hepatocellular carcinoma cells under hypoxia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Caspase 3; Cell Adhesion Molecules; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Oxides; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
Cryptotanshinone enhances the effect of Arsenic trioxide in treating liver cancer cell by inducing apoptosis through downregulating phosphorylated- STAT3 in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Down-Regulation; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Oxides; Phenanthrenes; Phosphorylation; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2017 |
Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization.
Topics: Androstadienes; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Liver Neoplasms; Metabolic Networks and Pathways; Oxides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Wortmannin | 2009 |
Possible roles of a tumor suppressor gene PIG11 in hepatocarcinogenesis and As2O3-induced apoptosis in liver cancer cells.
Topics: Adult; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Child; Cycloheximide; Dactinomycin; Down-Regulation; Female; Gene Expression; Gene Knockdown Techniques; Genes, Tumor Suppressor; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Nucleic Acid Synthesis Inhibitors; Oxides; Protein Synthesis Inhibitors | 2009 |
The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Oxides; Phosphorylation; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Retinoblastoma Protein; Stomach Neoplasms; Time Factors; Tumor Suppressor Protein p53; Up-Regulation; Verapamil | 2009 |
Nanosized As2O3/Fe2O3 complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biocompatible Materials; Cell Line, Tumor; Female; Ferric Compounds; Humans; Hyperthermia, Induced; Liver Neoplasms; Magnetics; Male; Materials Testing; Medicine, Chinese Traditional; Mice; Mice, Nude; Nanospheres; Oxides; Random Allocation; Swine; Transplantation, Heterologous | 2009 |
Arsenic trioxide inhibits metastatic potential of mouse hepatoma H22 cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Liver Neoplasms; Lung Neoplasms; Male; Matrix Metalloproteinase 2; Mice; NM23 Nucleoside Diphosphate Kinases; Oxides; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2009 |
Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Caspase 9; Cell Line, Tumor; Cell Survival; Drug Synergism; Genistein; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Oxides; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2010 |
Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Drug Synergism; Genistein; Hep G2 Cells; Humans; Liver Neoplasms; Mice; NF-kappa B; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2011 |
microRNA expression alteration after arsenic trioxide treatment in HepG-2 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Reporter; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Oxides; Phosphoprotein Phosphatases; Protein Phosphatase 2C; Reverse Transcriptase Polymerase Chain Reaction; Transfection | 2011 |
Normoxically overexpressed hypoxia inducible factor 1-alpha is involved in arsenic trioxide resistance acquisition in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lipid Peroxidation; Liver Neoplasms; Membrane Potential, Mitochondrial; Nitric Oxide; Oxides; Oxygen; Reactive Oxygen Species; Tumor Cells, Cultured | 2011 |
Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Humans; Inhibitor of Apoptosis Proteins; Interferon Inducers; Liver Neoplasms; Mitochondria; Oxides; Poly I-C; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Survivin; Toll-Like Receptor 3 | 2011 |
[Anti-angiogenesis effect of arsenic trioxide plus cinobufacin on human hepatocarcinoma transplantation model nude mice].
Topics: Amphibian Venoms; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Oxides; Phytotherapy; Xenograft Model Antitumor Assays | 2011 |
Arterial embolization hyperthermia using As2O3 nanoparticles in VX2 carcinoma-induced liver tumors.
Topics: Angiography; Animals; Arsenic Trioxide; Arsenicals; Embolization, Therapeutic; Hyperthermia, Induced; Immunohistochemistry; Liver; Liver Function Tests; Liver Neoplasms; Male; Microvessels; Nanoparticles; Necrosis; Oxides; Platelet Endothelial Cell Adhesion Molecule-1; Rabbits; Survival Analysis; Temperature; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Synergic effect of 3'-azido-3'-deoxythymidine and arsenic trioxide in suppressing hepatoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Caspase 3; Cell Growth Processes; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Oxides; Telomerase; Xenograft Model Antitumor Assays; Zidovudine | 2011 |
Pharmacokinetics of arsenic trioxide (As₂O₃) in Chinese primary hepatocarcinoma patients.
Topics: Area Under Curve; Arsenic Trioxide; Arsenicals; Asian People; Carcinoma, Hepatocellular; Female; Half-Life; Humans; Injections, Intravenous; Liver Neoplasms; Male; Middle Aged; Oxides | 2011 |
Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Topics: 3' Untranslated Regions; Antigens, Surface; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; ELAV Proteins; ELAV-Like Protein 1; ErbB Receptors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Liver Neoplasms; Models, Biological; Oxides; Phosphatidylinositol 3-Kinases; Repressor Proteins; RNA Stability; RNA-Binding Proteins; RNA, Messenger; Signal Transduction; Transcription, Genetic; Transforming Growth Factor beta | 2011 |
Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Capecitabine; Carcinoma, Hepatocellular; Cell Line; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorescent Dyes; Fluorouracil; Glycoproteins; Hep G2 Cells; Humans; Immunohistochemistry; Interferon-alpha; Liver Neoplasms; Oxides; Peptides; Rhodamine 123; Thy-1 Antigens | 2011 |
Arsenic trioxide inhibits HCCLM3 cells invasion through de novo ceramide synthesis and sphingomyelinase-induced ceramide production.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Ceramides; Humans; Liver Neoplasms; Matrix Metalloproteinase 9; Microscopy, Fluorescence; Neoplasm Invasiveness; Oxides; Sphingomyelin Phosphodiesterase | 2012 |
Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Diterpenes, Kaurane; Drug Synergism; Female; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; NF-kappa B; Oxides; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; X-Linked Inhibitor of Apoptosis Protein | 2012 |
Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cyclin B; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Nuclear Proteins; Oxides; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA, Small Interfering; Signal Transduction | 2012 |
Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
Topics: Adult; AMP-Activated Protein Kinases; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; Cell Survival; Drug Synergism; Enzyme Activation; Fluorouracil; Gene Expression Regulation, Enzymologic; Growth Inhibitors; Hep G2 Cells; Hepatic Stellate Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Oxides; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Thymidylate Synthase; Time Factors | 2012 |
[Inhibitory effect of arsenic trioxide on invasion in human hepatocellular carcinoma SMMC-7721 cells and its mechanism].
Topics: Arsenic Trioxide; Arsenicals; Basigin; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Oxides | 2012 |
[Comparison of antitumor efficacy between arsacetyl and arsenic trioxide in vitro].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; DNA Fragmentation; Drug Screening Assays, Antitumor; Endothelium, Vascular; Flow Cytometry; G1 Phase; Humans; Inhibitory Concentration 50; Liver Neoplasms; Oxides; Resting Phase, Cell Cycle; Tumor Cells, Cultured | 2002 |
Blockage of multidrug resistance-associated proteins potentiates the inhibitory effects of arsenic trioxide on CYP1A1 induction by polycyclic aromatic hydrocarbons.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinogens; Carcinoma, Hepatocellular; Cell Survival; Cytochrome P-450 CYP1A1; Dioxins; Drug Synergism; Enzyme Induction; Genes, Reporter; Hepatocytes; Humans; Immunoblotting; In Vitro Techniques; Liver Neoplasms; Mitochondrial Proteins; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oxides; Polycyclic Aromatic Hydrocarbons; Protein Processing, Post-Translational; Reactive Oxygen Species; Ribosomal Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
Synergistic effect of cell differential agent-II and arsenic trioxide on induction of cell cycle arrest and apoptosis in hepatoma cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Cycle; Cell Survival; Flow Cytometry; Growth Inhibitors; Humans; Liver Neoplasms; Oxides; Tumor Cells, Cultured | 2003 |
Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Differentiation; Coculture Techniques; Glutathione Peroxidase; Hematopoietic Stem Cells; Humans; Hydrogen Peroxide; K562 Cells; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Lymphoma; Methylation; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tumor Cells, Cultured | 2003 |
Arsenic trioxide induces apoptosis of rat hepatocellular carcinoma cells in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Cycle; Female; Liver Neoplasms; Male; Microscopy, Electron; Oxides; Rats; Rats, Wistar; Tumor Cells, Cultured | 2003 |
[Mechanism of arsenic trioxide-induced apoptosis in hepatic blastoma cells HepG2].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Hep G2 Cells; Hepatoblastoma; Humans; Liver Neoplasms; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins | 2003 |
Antitumor effect of arsenic trioxide in murine xenograft model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Brain; Carcinoma, Hepatocellular; Humans; In Situ Nick-End Labeling; Injections, Intravenous; Kidney; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Oxides; Spectrometry, X-Ray Emission; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2).
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Survival; Cloning, Molecular; Gene Expression Regulation, Neoplastic; Genes, Reporter; HSP70 Heat-Shock Proteins; Humans; Liver Neoplasms; Metallothionein; Oxides; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Transcriptional Activation; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
[Application of arsenic trioxide in comprehensive therapy of liver carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Oxides | 2003 |
Radiofrequency ablation: Effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model.
Topics: Adrenergic Agonists; Anesthetics, Inhalation; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Catheter Ablation; Disease Models, Animal; Epinephrine; Halothane; Kidney; Kidney Neoplasms; Laser-Doppler Flowmetry; Liver; Liver Neoplasms; Oxides; Rabbits; Regional Blood Flow | 2004 |
[Study on effect of arsenic trioxide on adhesion and invasion of human hepatocarcinoma cells in vitro].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Humans; Hyaluronan Receptors; Intercellular Adhesion Molecule-1; Liver Neoplasms; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neoplasm Invasiveness; Oxides | 2004 |
[The effect and mechanism of arsenic trioxide on hepatocellular carcinoma].
Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemotherapy, Cancer, Regional Perfusion; Female; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Middle Aged; Oxides | 2005 |
Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; B7 Antigens; B7-1 Antigen; Carcinoma, Hepatocellular; Combined Modality Therapy; Gene Transfer Techniques; Humans; Immunotherapy; Interferon-gamma; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Oxides; Receptors, Immunologic; T-Lymphocytes, Cytotoxic | 2006 |
Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Neoplasm; Genes, p16; Glutathione S-Transferase pi; Hepatocytes; Humans; Liver Neoplasms; Male; Middle Aged; Oxides; RNA, Messenger; Tumor Suppressor Proteins | 2006 |
Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Free Radical Scavengers; Humans; Liver Neoplasms; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2006 |
Dithiothreitol abrogates the effect of arsenic trioxide on normal rat liver mitochondria and human hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dithiothreitol; Dose-Response Relationship, Drug; Electron Transport Chain Complex Proteins; Environmental Pollutants; Humans; Liver Neoplasms; Male; Membrane Potential, Mitochondrial; Mitochondria, Liver; Oxides; Oxygen Consumption; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2008 |
[Inhibitory effect of arsenic trioxide on proliferation of human hepatocellular carcinoma cell line SMMC-7721 and the mechanism].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; COP9 Signalosome Complex; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Oxides; Peptide Hydrolases | 2007 |
Redox status of thioredoxin-1 (TRX1) determines the sensitivity of human liver carcinoma cells (HepG2) to arsenic trioxide-induced cell death.
Topics: Animals; Arsenic Trioxide; Arsenicals; Binding Sites; Carcinoma, Hepatocellular; Caspases; Cell Death; Cell Line, Tumor; Cytochromes c; Dinitrochlorobenzene; Drug Screening Assays, Antitumor; Enzyme Activation; Humans; Liver Neoplasms; Mice; Mitochondria; Mitochondrial Swelling; Mutant Proteins; NADP; Oxidation-Reduction; Oxides; Reactive Oxygen Species; Recombinant Proteins; RNA Interference; Thioredoxins | 2008 |
[Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Oxides; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Influence of vinyl chloride monomer (VCM) and As2O3 on rat liver cell proliferation after partial hepatectomy.
Topics: Alkaline Phosphatase; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Hepatectomy; Liver; Liver Neoplasms; Liver Regeneration; Male; Mitosis; Oxides; Rats; Vinyl Chloride; Vinyl Compounds | 1980 |
[An experimental study on arsenic trioxide-selectively induced human hepatocarcinoma cell lines apoptosis and its related genes].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; fas Receptor; Genes, bcl-2; Humans; In Situ Nick-End Labeling; Liver Neoplasms; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; S Phase; Tumor Cells, Cultured | 2000 |
Atrazine potentiation of arsenic trioxide-induced cytotoxicity and gene expression in human liver carcinoma cells (HepG2).
Topics: Arsenic Trioxide; Arsenicals; Atrazine; Cell Line, Transformed; Cell Survival; Cyclic AMP Response Element-Binding Protein; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Gene Expression; Gene Expression Profiling; Hepatocytes; HSP70 Heat-Shock Proteins; Humans; Liver Neoplasms; Metallothionein; Oxides; Proto-Oncogene Proteins c-fos | 2001 |
[Arsenic trioxide in the treatment of advanced primary liver and gallbladder cancer].
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gallbladder Neoplasms; Humans; Injections, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxides; Quality of Life; Treatment Outcome | 2001 |
Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Carcinoma, Hepatocellular; Caspases; Cell Division; Cell Nucleus; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Humans; Kinetics; Liver Neoplasms; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2002 |
Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: inhibition of proliferation and induction of apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Caspase 3; Caspases; Cell Cycle; Cell Division; Enzyme Activation; Humans; Liver Neoplasms; Mitochondria; Oxides; Tumor Cells, Cultured | 2002 |
Design, synthesis and antitumor evaluation of novel 1H-indole-2-carboxylic acid derivatives targeting 14-3-3η protein.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Apoptosis; Carboxylic Acids; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Liver Neoplasms; Molecular Docking Simulation; Structure-Activity Relationship | 2022 |